{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/A4001007","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00643643","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"true","masked_subject":"true","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized Controlled Trial","arm_groups":[{"arm_group_label":"A","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"B","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"C","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"D","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"E","arm_group_description":"","arm_type":"Placebo Comparator"}],"assignment":"Single Group","brief_summary":"To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:06:58","criteria":"Inclusion Criteria: Inclusion criteria: - Male with HIV or surgically sterilized female with HIV showing no symptoms of HIV - Weight between 50 and 90kg and within the permitted range for their height Exclusion Criteria: Exclusion criteria: -Subjects with a CD4 count less than 250cells/mm3 or HIV viral load of less than 5000 copies/mL -Subjects with acquired immune deficiency syndrome (AIDS) or a previous AIDS diagnosis -Subjects whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion -Subjects who have taken anti-retroviral drugs in the eight weeks prior to the study screening visit","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"41","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"c50bf1dd-2b9d-5901-9ba0-0dd60931a64b","internal":{"content":null,"contentDigest":"3cdeda63495bce6a59198309a258aef2","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: Inclusion criteria: - Male with HIV or surgically sterilized female with HIV showing no symptoms of HIV - Weight between 50 and 90kg and within the permitted range for their height Exclusion Criteria: Exclusion criteria: -Subjects with a CD4 count less than 250cells/mm3 or HIV viral load of less than 5000 copies/mL -Subjects with acquired immune deficiency syndrome (AIDS) or a previous AIDS diagnosis -Subjects whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion -Subjects who have taken anti-retroviral drugs in the eight weeks prior to the study screening visit","interventions":[{"arm_group_label":"A","intervention_description":"25 mg oral tablet once daily for 10 days","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"B","intervention_description":"50 mg oral tablet twice daily for 10 days","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"C","intervention_description":"100 mg oral tablet twice daily for 10 days","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"D","intervention_description":"300 mg oral tablet twice daily for 10 days","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"E","intervention_description":"Matching placebo oral tablet twice daily for 10 days","intervention_name":"Placebo","intervention_type":"Other"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["HIV","Treatment Naïve"],"last_follow_up_date":"06/01/2003 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001007&StudyName=Pharmacokinetics%2C%20Pharmacodynamics%2C%20And%20Safety%20Of%20Maraviroc%20%28UK-427%2C857%29%20In%20Patients%20With%20Human%20Immunodeficiency%20Virus"},{"description":"Link to ClinicalStudyResults.org","url":"http://www.clinicalstudyresults.org/drugdetails/?study_name=A4001007&sort=c.company_name&page=1&drug_id=3476"}],"locations":[{"City":"Utrecht","Latitude":"52.0857988","CountryDisplay":"Netherlands","Longitude":"5.1788155","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"3584 CX","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.4843083","CountryDisplay":"United Kingdom","Longitude":"-0.1816441","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"SW10 9NH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"LONDON","Latitude":"51.5532242","CountryDisplay":"United Kingdom","Longitude":"-0.1653236","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"NW3 2QG","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bonn","Latitude":"50.73743","CountryDisplay":"Germany","Longitude":"7.0982068","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"53105","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Koeln","Latitude":"50.937531","CountryDisplay":"Germany","Longitude":"6.9602786","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"50924","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Muenchen","Latitude":"48.1340355","CountryDisplay":"Germany","Longitude":"11.5571732","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"80336","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Double-Blind","maximum_age_raw":"55 Years","maximum_age":"55","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 22:48:30","number_of_arms":"5","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.","org_study_id":"A4001007","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"PHASE II","primary_compl_date":"06/01/2003 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Change from baseline in viral load","outcome_time_frame":"Day 11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Pharmacokinetic profile of UK-427,857","outcome_time_frame":"Days 1 and 10","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Receptor saturation","outcome_time_frame":"Days 1, 5, 10, 11, 13, 15, 19, 40","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"12-lead electrocardiography","outcome_time_frame":"Days 1-11 and Day 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time course of viral load from baseline to follow-up","outcome_time_frame":"Days 1-15 and Days 19, 22, 25, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to rebound of viral load","outcome_time_frame":"Days 1-15 and Days 19, 22, 25, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The relationship of change in viral load (from baseline to day 11) versus average (Days 1-11) and trough (Day 10) plasma concentrations","outcome_time_frame":"Days 1-11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The relationship of change in viral load (from baseline to day 11) versus mean receptor saturation (Day 10)","outcome_time_frame":"Days 1-11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The relationship of change from baseline in viral load versus baseline virus susceptibility (IC 50 and IC 90)","outcome_time_frame":"Days 1-11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Adverse events","outcome_time_frame":"Days 1-40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Laboratory safety testing","outcome_time_frame":"Days 1, 3, 7, 11, 15, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Physical examination","outcome_time_frame":"Days 1, 11, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Supine and standing blood pressure and pulse rate","outcome_time_frame":"Days 1-11 and Day 40","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Pfizer"]},"start_date":"10/01/2002 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":true}},"pageContext":{"studyId":"A4001007"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}